Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Diagnostics Makers Aim To Produce 25 Million COVID-19 Tests By End Of April

Executive Summary

The head of the largest medical device lobby group told reporters the industry hopes to get 25 million diagnostic tests produced by the end of the month to fight the ongoing coronavirus pandemic in the US.

You may also be interested in...



FDA: Rapid Antigen COVID-19 Tests At Risk For False Positives

An alert from the agency warns that the tests, which have become widely used for their speed and portability, carry a risk of false positives.

COVID-19 Registry Aims To Map And Address Potential Test Shortages

Medtech industry group AdvaMed has developed a registry to share data on how many COVID-19 diagnostic tests are available and where they are, with a goal of foreseeing and nipping in the bud potential test shortages. Thirteen diagnostic manufacturers – including Abbott, Roche, Siemens and Thermo Fisher Scientific – have partnered with AdvaMed on the initiative.

Contrary To Trump, Gottlieb Says The US Had ‘Late Start’ Testing For COVID-19

Despite the White House’s insistence it has been quick and decisive in its response to the COVID-19 crisis, former FDA commissioner Scott Gottlieb – who has been advising the administration – said on 6 May that the government should’ve responded months sooner to ensure there was enough testing.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT126639

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel